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With great interest, we read the article by Kuo et al1 in the
Journal of Microbiology, Immunology and Infection, which
reports that Burkholderia cepacia is an important pathogen
in elderly patients, and the success rate of tigecycline
therapy for osteomyelitis is only 50%. Here, we report a
case of recurrent osteomyelitis and bacteremia caused by
B. cepacia. The patient received salvage therapy with
tigecycline and trimethoprim/sulfamethoxazole success-
fully during the second treatment course.
An 80-year-old female patient suffered from falling down
and traumatic injury of chest wall sternal bone. Fever, chills,
and pus discharge from the sternal bone were noted 6 days
later. The blood and pus culturework-ups were performed at
admission, and both grew B. cepacia. The susceptibility
testing of B. cepacia showed that it was sensitive to cefta-
zidime, meropenem, trimethoprim/sulfamethoxazole, and
tigecycline; intermittent to moxifloxacin; and resistant to
amikacin and ciprofloxacin. The patient was initially treated
with ceftazidime 2 g intravenously q8h for 14 days. Then she
received oral trimethoprim/sulfamethoxazole 160/800 mg
twice daily and oral moxifloxacin 400 mg every day at the
outpatient clinic for 3 months. Her clinical condition
improved, and the laboratory data of C-reactive protein and
erythrocyte sediment rate revealed a normal range. How-
ever, unfortunately, she suffered from fever, sternal bone
pain, and pus discharge 1 month after discontinuing the oral
antibiotic therapy. She was readmitted to a ward, and
received tigecycline 50 mg intravenously q12h and 100 mg
stat, plus trimethoprim/sulfamethoxazole 160/800 mg
intravenously twice daily as salvage therapy for 1 month. A
gallium scan of the whole body showed negative finding, and
C-reactive protein and erythrocyte sediment rate at the
outpatient clinic were also within the normal range 3months
after discontinuing the antibiotic therapy.
B. cepacia (formerly Pseudomonas cepacia) is increas-
ingly recognized as an important pathogen in elderly and
critically ill patients.1,2 It is an aerobic, Gram-negative,Please cite this article in press as: Lee W-S, et al., Successful salvage
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uncommon in community infections, and B. cepacia
bacteremia complicated with osteomyelitis is rare. Recent
observations suggest that the environment serves as a
source of this bacterium.2,3 B. cepacia exhibits extensive
antibiotic resistance in vitro, and this limits the thera-
peutic options. Some antibiotics such as ceftazidime, car-
bapenem, trimethoprim/sulfamethoxazole, and
fluoroquinolones have shown in vitro activities against this
bacterium, and some combinations have shown synergy.2e6
Ceftazidime combined with amikacin has been shown to
have the best synergistic antimicrobial activities,2 but
treatment failure was noted in our patient with intravenous
administration of ceftazidime alone. Tigecycline, the first
glycylcycline, has been approved by the US Food and Drug
Administration (FDA) for the treatment of complicated skin
and skin structure infections, but not for the bone and joint
infections. In a review of the literature, the most common
combination therapy of tigecycline for multidrug resistant
organisms was Acinetobacter baumannii.1,5 The clinical
experience of tigecycline combined with trimethoprim/
sulfamethoxazole for B. cepacia osteomyelitis with
bacteremia is extremely limited.1e3,6 In view of limited
drug choices and refractory therapy in such aged patients
with osteomyelitis caused by multidrug-resistant B. cepa-
cia, tigecycline may be considered as one of the alternative
choices.
Conflicts of interest
The authors have no conflicts of interest to declare.
References
1. Kuo SC, Wang FD, Fung CP, Chen LY, Chen SJ, Chiang MC, et al.
Clinical experience with tigecycline as treatment for serious
infections in elderly and critically ill patients. J Microbiol
Immunol Infect 2011;44:45e51.therapy with tigecycline and trimethoprim/sulfamethoxazole for
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
by Elsevier Taiwan LLC. All rights reserved.
2 Correspondence
+ MODEL2. Huang CH, Jang TN, Liu CY, Fung CP, Yu KW, Wong WW. Char-
acteristics of patients with Burkholderia cepacia bacteremia. J
Microbiol Immunol Infect 2001;34:215e9.
3. Lu DC, Chang SC, Chen YC, Luh KT, Lee CY, Hsieh WC. Bur-
kholderia cepacia bacteremia: a retrospective analysis of 70
episodes. J Formos Med Assoc 1997;96:972e8.
4. Wang CH, Lin JC, Lin HA, Chang FY, Wang NC, Chiu SK, et al.
Comparisons between patients with trimetho-
primesulfamethoxazole-susceptible and trimethoprime
sulfamethoxazole-resistant Stenotrophomonas maltophilia
monomicrobial bacteremia: a 10-year retrospective study. J
Microbiol Immunol Infect 2014. http://dx.doi.org/10.1016/j.
jmii.2014.06.005.
5. Teng SO, Yen MY, Ou TY, Chen FL, Yu FL, Lee WS. Comparison
of pneumonia- and non-pneumonia-related Acinetobacter
baumannii bacteremia: impact on empiric therapy and anti-
biotic resistance. J Microbiol Immunol Infect 2014. http://dx.
doi.org/10.1016/j.jmii.2014.06.011.
6. Nord CE, Wadstrom T, Wretlind B. Synergistic effect of colo-
nization of sulfamethoxazole, trimethoprim and colistin
against Pseudomonas maltophilia and Pseudomonas cepacia.
Antimicrob Agents Chemother 1974;6:521e3.
Wen-Sen Lee
Tai-chin Hsieh
Tsong-Yih Ou
Fu-Lun Chen*
Division of Infectious Diseases, Department of Internal
Medicine, Wan Fang Medical Center, Taipei Medical
University, Taipei, TaiwanPlease cite this article in press as: Lee W-S, et al., Successful salvage
recurrent osteomyelitis caused by Burkholderia cepacia, Journal of M
10.1016/j.jmii.2014.12.004Department of Internal Medicine, School of Medicine,
Taipei Medical University, Taipei, Taiwan
Fang-Lan Yu
Division of Bacteriology, Department of Laboratory, Wan
Fang Medical Center, Taipei Medical University, Taipei,
Taiwan
Department of Internal Medicine, School of Medicine,
Taipei Medical University, Taipei, Taiwan
Shio-Shin Jean
Chin-Wang Hsu
Department of Emergency, Wan Fang Medical Center,
Taipei Medical University, Taipei, Taiwan
School of Medicine, Taipei Medical University, Taipei,
Taiwan
*Corresponding author. Division of Infectious Disease,
Department of Internal Medicine, Wan Fang Medical Center,
Taipei Medical University, Number 111, Section 3, Hsing
Long Road, Taipei 116, Taiwan.
E-mail address: 89425@wanfang.gov.tw (F.-L. Chen)
25 November 2014
Available online - - -therapy with tigecycline and trimethoprim/sulfamethoxazole for
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
